Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Maha H A HussainMasha KocherginskyArchana M AgarwalNabil AdraJingsong ZhangChanning J PallerJoel PicusZachery R ReichertRussell Zelig SzmulewitzScott T TagawaTimothy M KuzelLatifa A BazziStephanie Daignault-NewtonYoung E WhangRobert DreicerRyan D StephensonMatthew B RettigDaniel ShevrinTravis A GerkeArul M ChinnaiyanEmmanuel S AntonarakisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
In mCRPC patients with BRCA1/2 or ATM HRRm, abiraterone/prednisone + olaparib was well tolerated and demonstrated longer PFS versus either agent alone or sequentially.